• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Pressemeddelelse

Vækstaktier.dk: SMS: Prelude to the 2025/26 Half-Year Report

Scandinavian Medical Solutions

Scandinavian Medical Solutions is expected to publish its half-year report for the 2025/26 financial year on 19 May 2026.

The upcoming half-year report from Scandinavian Medical Solutions covers the first six months of a financial year that has seen mixed developments, with both new orders and lowered expectations for the full financial year.

Scandinavian Medical Solutions began the financial year with several announced sales of used diagnostic imaging equipment. In autumn 2025, SMS announced four orders across the US market and Eastern Europe. In December, this was followed by the sale of a used PET/CT scanner to a customer in the US, and in January 2026 a PET/MR scanner was sold to an Eastern European buyer for DKK 3.5-5 million.

In April, however, the company lowered its guidance for the full financial year. SMS now expects revenue in the range of DKK 190-220 million, compared with the previous DKK 220-250 million, while EBITDA has been reduced from DKK 11-15 million to DKK 0-5 million. The reasons for the downgrade were increased global uncertainty, including trade barriers in the US, geopolitical tensions in the Middle East and rising oil prices, which have led several of the company's customers to postpone investments.

The upcoming half-year financial statements will therefore be the first consolidated measure of how these challenges are affecting the company's financial performance. It will also be interesting to gain better insight into what the company's management expects from the second half of the financial year. The report on 19 May is therefore expected to provide an updated picture of how robust the core business is under the current market conditions.

Contacts
Email: markus@vaekstaktier.dk
Telephone: +45 50 42 99 18

About Us
Disclaimer: Vaekstaktier has a paid IR-partnership with the company mentioned. The content is for informational purposes and is a redistribution of the company’s own communications.

Website: vaekstaktier.dk

Attachments
SMS: Prelude to the 2025/26 Half-Year Report